Syntara’s SNT-5505 moves ahead in clinical trials
Syntara has announced that a Phase 2 trial evaluating the combination treatment of its SNT-5505 with chemotherapy will go ahead for patients with a form of blood cancer. In a statement this week, the ASX-listed drug development company – formerly known as Pharmaxis – said that its SNT-5505 (previously known as PXS-5505) would be trialled…